Enhancement of Tumor Cell Death by Combining gef Gene Mediated Therapy and New 1,4-Benzoxazepin-2,6-Dichloropurine Derivatives in Breast Cancer Cells

• Published in: Frontiers in pharmacology 2018-07, Vol.9, p.798-798
• Main Authors: Ramírez, Alberto, Conejo-García, Ana, Griñán-Lisón, Carmen, López-Cara, Luisa C, Jiménez, Gema, Campos, Joaquín M, Marchal, Juan A, Boulaiz, Houria
• Format: Article
• Language: English
• Subjects: 4-benzoxazepin-2; 6-dichloropurine; breast cancer; combined therapy; gef gene; Pharmacology
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2018.00798

New treatment modalities are urgently needed to better manage advanced breast cancer. Combination therapies are usually more effective than monotherapy. In this context, the use of cyclic and acyclic -acetals derivative compounds in combination with the suicide gene shown a potent anti-tumor activity and represent a new generation of anticancer agents. Here, we evaluate the use of the gene to promote and increase the anti-tumor effect of cyclic and acyclic -acetals purine derivatives and elucidate their mechanisms of action. Among all compounds tested, those with a nitro group and a cyclic pattern structures (FC-30b2, FC-29c, and bozepinib) are the most benefited from the gene effect. These compounds, in combination with gene, were able to abolish tumor cell proliferation with a minimal dose leading to more effective and less toxic chemotherapy. The effect of this combined therapy is triggered by apoptosis induction which can be found deregulated in the later stage of breast cancer. Moreover, the combined therapy leads to an increase of cell post-apoptotic secondary necrosis that is able to promote the immunogenicity of cancer cells leading to a successful treatment. This data suggests that this novel combination therapy represents a promising candidate for breast cancer treatment.